Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis

Obesity Clinical Trial

— PRECISE  

Official title:

Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04585711
• Other study ID #: Pro00105975
• Secondary ID: 1K23AR075874-01A
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: July 1, 2024
• Est. completion date: February 28, 2025

Study information

• Verified date: May 2024
• Source: Duke University
• Contact: Balevic Stephen, MD
• Phone: 919-668-4544
• Email: Stephen.balevic[@]duke.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to learn more about how adult and children's bodies use etanercept and how bodyweight influences how well etanercept works. This study will help us understand the proper dose of etanercept in obese children and adults.

Description:

PRECISE is an open-label, single arm, single-center site study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of dosing interval-optimized etanercept in obese patients with Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA). Approximately 30 patients with JIA or RA who are starting etanercept standard-of-care will take part in the study.

Eligible patients will have blood collections before and after starting the biologic of interest to assess PK and disease activity. Five (5) blood samples will be collected through a combination of clinic and home visits.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: February 28, 2025
• Est. primary completion date: February 28, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 65 Years

Eligibility

Inclusion Criteria

• Diagnosis of Rheumatoid Arthritis (RA) according to the 2010 American College of Rheumatology Classification Criteria (patients greater than or equal to 16 years of age at screening)

• Diagnosis of Juvenile Idiopathic Arthritis (JIA) according to the International League Against Rheumatism Classification Criteria (children less than 16 years of age at screening)

• Initiating treatment with etanercept as standard of care by a patient's primary rheumatologist

• Obese at baseline, defined as a body mass index (BMI) greater than or equal to 30 kg/m2 in subjects greater than or equal to 18 years of age, and a BMI greater than or equal to 95th percentile for age and sex in subjects less than18 years of age

• Active disease at screening, defined as a DAS28 > 3.2 in adults and JADAS27 > 3.8 in children

• Patients using oral corticosteroids (<10 mg) or DMARDs must be on a stable dose for at least 4 weeks prior to screening

Exclusion Criteria

• Receipt of any investigational medical product within the past 12 months

• Positive urine pregnancy test at screening or planned pregnancy during the study period

• Prior exposure to etanercept or any other biologic agent within 5 drug half-lives

• Contraindication to etanercept (e.g., allergy, current or chronic infection [positive tuberculosis screening test, positive hepatitis B surface antigen, positive hepatitis C antibody])

• Personal history of ever having malignancy, lymphoproliferative disease, or demyelinating disease

• Screening safety labs with a hemoglobin of = 9 g/dL, white blood cell count <3.0x109L, platelets <125,000 x109L, AST/ALT more than 2x the upper limit of normal, or creatinine > 2 mg/dL for adults and >1 mg/dL for children

• Evidence of erosive osteoarthritis on plain films (if available at time of screening), or severe osteoarthritis (defined as any anticipated need for joint replacement within the next year) as judged by the primary rheumatologist

• History of any opportunistic infections, or recent severe infection in the 3 months prior to screening (e.g., hepatitis, pneumonia, pyelonephritis, bacteremia)

• Heart failure with NYHA classification 3 or more

• Severe functional impairment status, defined as HAQ >2 and CHAQ >1.75

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Juvenile
• Juvenile Idiopathic Arthritis
• Obesity
• Rheumatoid Arthritis

Intervention

Drug:
• Etanercept Optimal dosing
Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clearance (CL)	Clearance at steady state as measured by PK sampling	6 weeks
Primary	Volume of distribution (V)	Volume of distribution at steady state as measured by PK sampling	6 weeks
Secondary	Median prediction error between observed and model predicted concentrations	We will use PK/PD models to simulate drug concentration for each individual subject. We measure the error between simulated and observed plasma concentrations.	6 weeks
Secondary	mean change in DAS28/JADAS27	We will score disease activity using the DAS28 (RA) or JADAS27 (JIA) at baseline and 6 week follow up. We will measure the change in score over 6 weeks.	Baseline, 6 weeks